Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2005-01-25
2005-01-25
Shukla, Ram R. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C435S006120, C435S007200, C435S377000, C536S023100, C424S009100, C514S04400A
Reexamination Certificate
active
06846799
ABSTRACT:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
REFERENCES:
patent: 5525625 (1996-06-01), Bridges et al.
patent: 5559111 (1996-09-01), Guschke
patent: 6037361 (2000-03-01), Roth et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: WO 9719065 (1997-05-01), None
patent: WO 9745412 (1997-12-01), None
patent: WO 9837881 (1998-09-01), None
patent: WO 9901421 (1999-01-01), None
patent: WO 9901426 (1999-01-01), None
patent: WO 9932121 (1999-07-01), None
patent: WO 0006560 (2000-02-01), None
patent: WO 0006561 (2000-02-01), None
patent: WO 0009485 (2000-02-01), None
patent: WO 0010588 (2000-03-01), None
patent: WO 0017162 (2000-03-01), None
Masui et al. Cancer Res. 1984 vol. 44, pp. 1002-1007.*
Yoneda et al. Cancer Res. 1991. vol. 51, pp. 4430-4435.*
Khetarpal et al. Drug Metabolism and Disposition. 1994. vol. 22, No. 2, pp. 216-223.*
Buchdunger et al. Proc. Natl. Acad. Sci. USA 1994 vol. 91, pp. 2334-2338.*
Giorgio Palu′ et al., In pursuit of new developments for gene therapy of human diseases, Journal of Biotechnology, 68 (1991) pp. 1-13.*
Stanley T. Crooke, Antisense Research and Application, pp. 1-50 (1998).*
Andrea D. Branch, A good antisense molecule is hard to find, TIBS 23-Feb. (1998.) pp. 45-50.*
Karen Pihl-Carey, Isis To Cronh's Disease Drug Fails in Phase III, Bioworld Today, vol. 10, No. 239, pp. 1-2 (1999).*
Grandis et al. (Jul. 24, 1997), “Inhibition of Epidermal Growth Factor Receptor Gene Expression and Function Decreases Proliferation of Head and Neck Squamos Carcinoma but not Normal Mucosal Epitherlial Cells.”Oncogene, vol. 15(4):406-416.
Donato et al (1989), “Tumor Necrosis Factor Modulates Epidermal Growth Factor Receptor Phosphorylation and Kinase Activity in Human Tumor Cells”,The Journal of Biological Chemistry, vol. 264(34):20474-20481.
Desseyn et al. (1997), “Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat”,The Journal of Biological Chemistry, vol. 272(6): 3168-3178.
Goldstein et al. (1995), “Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model”,Clinical Cancer Research, vol. 1: 1311-1318.
Kawamoto et al. (1983), “Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors fo epidermal growth factor by an anti-receptor monoclonal antibody”,Proc. Natl. Acad. Sci. USA, vol. 80: 1337-1341.
Kondapaka et al. (1996), “Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer”,Molecular and Cellular Endocrinology, vol. 117: 53-58.
Levitski (1994), “Signal-transduction therapy, a novel approach to disease management”,Eur. J. Biochem., vol. 226(1):1-13.
Lorimer, et al. (1995), “Immunotoxins that Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors”,Clinical Cancer Research, vol. 1: 859-864.
Petit er al. (1997), “Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2
eu Receptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells in Vitro and in Vivo”,American Journal of Pathology, vol. 151(6): 1523-1530.
Powis (1994), “Signaling pathways as targets for anticancer drug development”,Pharmac. Ther., vol. 62:57-95.
Schmidt et al. (1996), “Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα”,British Journal of Cancer, vol. 74: 853-862.
Takeyama et al. (1998), “Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion moleucles”,Am. J. Physiol., vol. 275:294-302.
Temann et al., (1997), “A Novel Role of Murine IL-4 In Vivo: Induction of MUC5AC Gene Expression and Mucin Hypersecretion”,Am J. Respir. Cell. Biol., vol. 16:471-478.
Ullrich et al. (1984), “Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.”Nature, vol. 309(5967):418-25.
Brown (1999), “Clinical Studies with matrix metallproteinase inhibitors.”APMIS, vol. 107:174-180.
Grandis, jr., et al. (1997), “Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not norml mucosal epithelial cells.”Oncogene, vol. 15(4):409-416.
Kumar et al. (1998), “Cooperative interaction of autocrine and paracrine mitogens for airway epithelial cells.”Cell Biology and Toxicology, vol. 14(4):293-299.
Lee et al. (2000), “Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals.”American Journal of Respiratory and Critical Care Medicine, vol. 161(6):1881-1886.
Prenzel et al. (1999), “EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF.”Nature, vol. 402:884-888.
Takeyama et al. (1999), “Epidermal growth factor system regulates mucin production in airways.”Proceedings of the national Academy of Sciences USA, vol. 96(6):3081-3086.
Takeyama et al. (2000), “Oxidative stress causes mucin synthesis via transactivation of epdiermal growth factor receptor: role of neutorphils.”Journal of Immunology, vol. 164(3):1546-1552.
Wojtowicz-Praga et al. (1997), “Matrix metalloproteinase inhibitors.Investigational New Drugs.” vol. 15:61-75.
Guzman et al. “Epidermal growth factor regulates expression of the mucous phenotype of rat tracheal epithelial cells”,Biochem. Biophys. Res. Com., (1995) vol. 217(2): 412-418.
Nadel Jay A.
Takeyama Kiyoshi
Borden Paula A.
Bozicevic Field & Francis LLP
Sherwood Pamela J.
Shukla Ram R.
The Regents of the University of California
LandOfFree
Preventing airway mucus production by administration of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventing airway mucus production by administration of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventing airway mucus production by administration of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3371856